

## Microba receives \$6.08 million R&D Tax Incentive Refund

- \$6,089,165 R&D Tax Incentive received for Research & Development Activities conducted during FY23
- The \$6.08m FY23 R&D Tax Incentive adds to Microba's strong financial position of \$27.85m in Cash or equivalents as at 31 December 2023

**Microba Life Sciences Limited** (ASX: MAP) ("Microba") is pleased to announce that the Company has received a \$6,089,165 Research & Development (R&D) Tax Incentive refund relating to R&D activities completed in the 2022/2023 financial year. The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities.

In addition to Microba's Australian Research & Development activities being eligible for the R&D Tax Incentive, Microba has also received four separate Advanced Overseas Findings from AusIndustry, which pre-approve eligible overseas expenditure for research and development activities across its Inflammatory Bowel Disease (IBD) and Autoimmune Diseases therapeutic programs. These four Advanced Overseas Findings cover total eligible overseas expenditure across FY22, FY23, FY24 and FY25.

**Microba's Chief Executive Officer, Dr. Luke Reid**, commented on the receipt of the R&D Tax Incentive, "We sincerely appreciate this ongoing support from the Australian Government. We believe that Microba's clinical stage therapeutics and diagnostic gastrointestinal tests can make a positive impact on Australian lives in the future, and the R&D Tax Incentive Program is assisting Microba to make this a reality".

*This announcement has been authorised for release by the Chair and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**  
Chief Executive Officer  
E: Luke.Reid@microba.com

**Investor / Media Relations**  
E: [investor@microba.com](mailto:investor@microba.com)  
W: <https://ir.microba.com/>  
[Join our Investor Mailing List](#)

### About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.